Skip to main content

Large Cap Biopharmaceuticals Performance Update 2018: Part 2

The biotech sector is in a strong bull market outperforming the Nasdaq and the S&P 500 however many analysts do not have a “strong buy” ( under 2.0) on large caps given the strong run over 12 months and YTD.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.